Sunil Healthcare Ltd

Sunil Healthcare, a microcap pharmaceutical company, reported a negative performance in the second quarter of fiscal year 2024-2025. However, the company's operating profit to interest ratio has improved, indicating better management of interest payments. On the other hand, operating cash flow and debtors turnover ratio have been consistently decreasing, while net sales and cash and cash equivalents have also shown a negative trend. Investors should carefully evaluate these factors before investing in the company's stock.

Sunil Healthcare, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 16, 2024. The stock has outperformed the sector by 3.72% and gained 14.12% in the last two days alone. It has also shown a remarkable growth of 94.96% in the past year, indicating its strong performance and potential in the pharmaceutical industry. However, MarketsMOJO has given a 'Sell' call for the stock, suggesting caution for potential investors.

Sunil Healthcare, a microcap pharmaceutical company, reported negative financial results for the quarter ending June 2024, with a score of -7. The company's debtors turnover ratio has been consistently falling, reaching its lowest at 2.22 times, potentially impacting cash flow and working capital management. Rising interest cost and debt-equity ratio raise concerns, leading to a 'Strong Sell' call by MarketsMOJO.

Sunil Healthcare, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 8th, 2024. The stock has consistently outperformed its sector and is currently trading above its moving averages, indicating a positive trend. Despite a 'Sell' call from MarketsMOJO, the company has shown strong growth and potential in the past year.

Sunil Healthcare, a microcap pharmaceutical company, reported a negative performance in the quarter ending March 2024, with a score of -6. The company's net sales decreased by 5.4% compared to the previous four quarters, and interest costs have increased by 22.22%. Investors should consider these factors before investing.

Sunil Healthcare, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on May 3rd, 2024. Despite a 'Sell' call from MarketsMOJO, the company's impressive performance in the past year, outperforming the sector by 1.42%, can be attributed to its consistent growth and strong financials.

Sunil Healthcare, a microcap pharmaceutical company, has reached a 52-week high of Rs.96.84 on May 2nd, 2024. Despite a 'Sell' call from MarketsMOJO, the stock has been trading higher than its moving averages and has outperformed the Sensex in the past year. Investors should carefully consider all factors before investing.

Sunil Healthcare, a microcap pharmaceutical company, has reached a 52-week high of Rs.93.12 on April 30, 2024. Despite a 'Sell' rating from MarketsMOJO, the stock has outperformed the sector by 4.56% and has seen a 55.07% increase in value in the past 9 days. It opened today with a gain of 4.99% and has maintained its high value throughout the day. Sunil Healthcare is also trading above its moving averages and has shown a remarkable 1-year performance of 41.31%, indicating its potential for growth in the future.

Sunil Healthcare, a microcap pharmaceutical company, has been making headlines in the stock market with its share price reaching a 52-week high on April 29, 2024. Despite being rated as a 'Sell' by MarketsMOJO, the stock has outperformed the sector and is currently trading higher than its moving averages. With a strong 1-year return and potential for growth, Sunil Healthcare is gaining attention from investors.

Sunil Healthcare, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on April 26, 2024. The stock has outperformed its sector by 4.7% and is currently trading higher than its moving averages. With a 40.67% increase in returns in the past 7 days, the company's strong financials and consistent growth in the pharmaceutical industry are driving its positive performance.

Sunil Healthcare, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on April 25th, 2024. The stock has outperformed its sector by 4.53% and gained 33.97% in the last 6 days. Despite being a microcap company, it has shown a strong performance in the past year, with a 28.00% return. However, according to MarketsMOJO, the stock call for Sunil Healthcare is currently a 'Strong Sell', indicating the need for caution and further research before investing.

Sunil Healthcare, a microcap pharmaceutical company, has reported a negative financial performance for the quarter ending December 2023. The company's profitability, sales, and efficiency have all declined, with a -185.6% decrease in Profit Before Tax (PBT) less Other Income and a -22.81% decline in Net Sales. Investors should consider these factors before investing.

Sunil Healthcare, a microcap pharmaceutical company, reported a 5.29% increase in net sales and a 71.88% decline in consolidated net profit for the quarter ended September 2023. Despite a 48.78% improvement in operating profit, interest expenses increased by 3.15%. Financial analysis shows negative performance, with a 'Strong Sell' stock call and a decline in net sales and profit after tax. Short-term liquidity and debtors turnover ratio have also deteriorated. Investors are advised to carefully consider these factors before making any investment decisions.